About 31 percent of patients with recalcitrant alopecia areata totalis or universalis had complete hair regrowth
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 15, 2023 (HealthDay News) — For patients with recalcitrant alopecia areata totalis or universalis, methotrexate combined with prednisone yields complete hair regrowth in about 31 percent of patients, according to a study published online March 8 in JAMA Dermatology.
Pascal Joly, M.D., Ph.D., from Rouen University Hospital in France, and colleagues examined the efficacy and tolerance of methotrexate alone or combined with low-dose prednisone in 89 patients with chronic and recalcitrant alopecia areata totalis or universalis in a randomized clinical trial. Patients were randomly assigned to methotrexate or placebo for six months; those with more than 25 percent hair regrowth at six months continued their treatment to 12 months, while those with less than 25 percent hair regrowth were re-randomly assigned to methotrexate plus prednisone or methotrexate plus placebo of prednisone.
The researchers found that complete or almost complete hair regrowth occurred at month 12 in one and zero patients who received methotrexate alone or placebo, respectively and in 20.0 percent of 35 patients who received methotrexate (for six or 12 months) plus prednisone, including 31.2 percent of 16 patients who received methotrexate for 12 months plus prednisone for six months. Compared with nonresponders, patients who achieved a complete response had a greater improvement in quality of life.
“The combination of methotrexate and low-dose prednisone can be considered as a therapeutic option in patients with recalcitrant types of alopecia areata totalis or universalis, even after the failure of previous systemic treatment,” the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Copyright © 2023 HealthDay. All rights reserved.
